STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #178 by analyst upside · 2026-08-13
APRE
Aprea Therapeutics, Inc.
Healthcare · Market Cap $8M · P/E 0x
ANALYST PRICE TARGET
+529.6%
implied upside to consensus target
Current Price $0.68
Consensus Target $4.3
Bull Target $6.0
Bear Target $1.2
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
0
Sell
0
52-Week Low $0.55
52-Week High $1.79
YTD Return -19.9%
FUNDAMENTALS
Market Cap $8M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.49
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.55
52-Week High $1.79
Current Price $0.68
Bear Target $1.2
Bull Target $6.0
● Now $0.68 ● Target $4.3
TRADING DATA
Avg Volume 99K
YTD Return -19.9%
Analyst Count 4
Consensus Buy
Upside to Target +529.6%
Last Updated 2026-08-13

ANALYST SUMMARY

Aprea Therapeutics, Inc. (APRE) is currently trading at $0.68 with a Wall Street consensus price target of $4.3, implying potential upside of 529.6% over the next 12 months. 4 analysts currently cover APRE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.0, while the most cautious has a target of $1.2.

APRE operates in the Healthcare sector with a market capitalisation of $8M. The stock is down 19.9% year-to-date and is currently trading near the lower end of its 52-week range of $0.55 – $1.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for APRE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush - Reiterated
Outperform → Outperform 2026-05-14 Building track record
Oppenheimer ● Initiated
Outperform 2026-05-07 14% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-03-31 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-31 31% win rate (48 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-02-10 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-01-29 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-12-18 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-01-15 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →